Active, not recruitingPHASE1, PHASE2NCT04349436
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Studying Cutaneous neuroendocrine carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Replimune Inc.
- Principal Investigator
- Jeannie Hou, MDReplimune Inc.
- Intervention
- RP1, intra-tumoral injection, oncolytic virus(biological)
- Enrollment
- 69 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2029
Study locations (28)
- Medical Dermatology Specialists, Phoenix, Arizona, United States
- Mayo Clinic Arizona, Phoenix, Arizona, United States
- University of California, San Diego, La Jolla, California, United States
- University of California, Los Angeles, Los Angeles, California, United States
- UCSF, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- University of Colorado Cancer Center School of Medicine, Aurora, Colorado, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- University of Chicago, Chicago, Illinois, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- Columbia University Medical Center, New York, New York, United States
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04349436 on ClinicalTrials.govOther trials for Cutaneous neuroendocrine carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07302347A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07288073TIL Therapy in cSCC and MCCKaram Khaddour, MD, MS
- RECRUITINGNCT07215988Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational StudyOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE2, PHASE3NCT06947928Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell CarcinomaTuHURA Biosciences, Inc.
- RECRUITINGPHASE1NCT06940440IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)TuHURA Biosciences, Inc.
- RECRUITINGNCT06780475Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell CarcinomaAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE1NCT07080242Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsSystImmune Inc.
- RECRUITINGNCT06608511Liquid Biomarker Study in Melanoma and Non-Melanoma Skin CancersUniversity of Wisconsin, Madison